
Company Information
Ask for more detail from the seller
Contact SupplierBevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds and inhibits biological activity of human vascular endothelial growth factor (VEGF). Bevacizumab has been approved for the treatment of Metastatic Colorectal Cancer (mCRC), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, Metastatic Renal Cell Carcinoma (mRCC) or Metastatic Carcinoma of the Cervix, etc.